Table 1.
Patient and tumor characteristics
| Trastuzumab group (n = 140) |
No-trastuzumab group (n = 83) |
p | |
|---|---|---|---|
| n (%) | n (%) | ||
| Age | 0.794 | ||
| <50 | 70 (50) | 43 (51.8) | |
| ≥50 | 70 (50) | 40 (48.2) | |
| T stage | 0.241 | ||
| T1–2 | 134 (95.7) | 77 (92.8) | |
| T3 | 6 (4.3) | 6 (7.2) | |
| Grade | 0.279 | ||
| 1–2 | 95 (67.9) | 63 (75.9) | |
| 3 | 45 (32.l) | 20 (24.1) | |
| Estrogen receptor | 0.393 | ||
| Positive | 53 (37.9) | 22 (26.5) | |
| Negative | 87 (62.1) | 61 (73.5) | |
| Pretreatment LN status | 0.097 | ||
| FNA or CNB+ | 50 (35.7) | 25 (30.1) | |
| SLNB+ | 19 (13.6) | 6 (7.2) | |
| SLNB– | 59 (42.1) | 37 (44.6) | |
| Unidentified | 12 (8.6) | 15 (18.1) | |
| Surgery | 0.337 | ||
| BCT | 51 (36.4) | 25 (30.1) | |
| Mastectomy | 89 (63.6) | 58 (69.9) | |
| ALND | 0.869 | ||
| Yes | 76 (54.3) | 46 (55.4) | |
| No | 64 (45.7) | 37 (44.6) | |
| Chemotherapy regimen | <0.001 | ||
| Anthracycline only or taxane only | 43 (30.7) | 53 (63.9) | |
| Anthracycline + taxane | 97 (69.3) | 30 (36.1) | |
| Radiotherapy | 0.233 | ||
| Yes | 62 (44.3) | 30 (36.1) | |
| No | 78 (55.7) | 53 (63.9) | |
| Residual DCIS | <0.001 | ||
| Yes | 28 (20) | 35 (42.2) | |
| No | 112 (80) | 48 (57.8) | |
| Endocrine therapy | 0.774 | ||
| Yes | 55 (39.3) | 31 (37.3) | |
| No | 85 (60.7) | 52 (62.7) | |
| Adjuvant chemotherapy | <0.001 | ||
| Yes | 15 (10.7) | 26 (31.3) | |
| No | 125 (89.3) | 57 (68.7) | |
LN, Lymph node; FNA, fine needle aspirate; CNB, core needle biopsy; SLNB, sentinel lymph node biopsy; BCT, breast-conserving therapy; ALND, axillary lymph node dissection; DCIS, ductal carcinoma in situ.